Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089635 | 0.99 | TGM2 (0.48) | TGM2EPHX2MAOBTRPV1NAMPT | |
| SCHEMBL2090181 | 0.88 | TRPV1 (0.39) | EPHX2TRPV1KIF11NPC1RAB9A | |
| SCHEMBL2092137 | 0.87 | TRPV1 (0.40) | EPHX2TRPV1KIF11NPC1RAB9A | |
| SCHEMBL2089248 | 0.85 | KMT2A (0.48) | EPHX2TRPV1ALDH1A1 | |
| SCHEMBL2090948 | 0.85 | TGM2 (0.44) | TGM2NPC1RAB9AALDH1A1 | |
| SCHEMBL2092083 | 0.84 | TGM2 (0.43) | TGM2NAMPTNPC1RAB9AALDH1A1 | |
| SCHEMBL2088774 | 0.84 | LMNA (0.43) | TGM2NPC1RAB9AALDH1A1 | |
| SCHEMBL2091320 | 0.84 | NPC1 (0.41) | EPHX2NPC1RAB9AALDH1A1 | |
| SCHEMBL2089169 | 0.84 | KMT2A (0.49) | EPHX2TRPV1ALDH1A1 | |
| SCHEMBL2094169 | 0.84 | GRIN2B (0.43) | TGM2EPHX2MAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190706-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | SCANIO MARC J C (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163914-B2 | Modulate neuronal nicotinic receptor activity; attention deficit disorder, Parkinson's, Tourette's, schizophrenia, cognitive deficits, dementia; acute pain, post-surgical pain, chronic pain, inflammatory pain; 2-[1-azatricyclo[3.3.1.13,7]dec-4-ylidene]-N-(4-methylphenyl)acetamide | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2069346-B1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | NAAA, AADAC, CD38 | TGM2 2493/4885EPHX2 995/4885MAOB 381/4885 |
| US-20120190706-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | NAAA, AADAC, CD38 | TGM2 2493/4885EPHX2 995/4885MAOB 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.